We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $281M
1-Year Est. Return 261.03%
This Fund
S&P 500
This Quarter Est. Return
+20.25%
1 Year Est. Return
+261.03%
3 Year Est. Return
+648.19%
5 Year Est. Return
+623.84%
10 Year Est. Return
–
AUM
$123M
AUM Growth
+$85.4M
Cap. Flow
+$71.3M
Cap. Flow %
57.76%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
DTIL icon
Precision BioSciences
DTIL
+$75.5M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$4.15M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DTIL icon
1
Precision BioSciences
DTIL
$189M
$76.6M 62%
+142,171
New +$75.5M
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
$29.8M 24.1%
1,526,122
-263,980
-15% -$4.15M
VYNE icon
3
VYNE Therapeutics
VYNE
$17.2M
$11.5M 9.29%
20,299
– –
VRNA
4
DELISTED
Verona Pharma
VRNA
$5.69M 4.61%
875,000
– –

Similar funds

FFP
Freedom Financial Partners Oakdale, Minnesota $281M AUM 16.89% 1-Year Est. Return
BDA
Borer Denton & Associates Blue Bell, Pennsylvania $280M AUM 7.09% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
SA
SoundView Advisors Olympia, Washington $281M AUM 17.96% 1-Year Est. Return
ACC
Acorn Creek Capital Fort Collins, Colorado $280M AUM 19.97% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $281M AUM 56.22% 1-Year Est. Return
IP
Investment Partners New Philadelphia, Ohio $281M AUM 20.9% 1-Year Est. Return

venBio Partners's Q1 2019 Portfolio in Review

As of Q1 2019, venBio Partners held 4 positions worth $123M, up 224% from $38.1M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners deployed $71.3M of net new capital in Q1 2019, opening 1 new position. Its largest new stake was Precision BioSciences: 142,171 shares worth $76.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Apellis Pharmaceuticals, an estimated $4.15M trimmed.

  • venBio Partners's largest Q1 2019 buy was Precision BioSciences: 142,171 shares worth $76.6M.
  • venBio Partners's biggest Q1 2019 reduction was Apellis Pharmaceuticals, cutting an estimated $4.15M.
  • venBio Partners's ten largest holdings make up 100% of its $123M portfolio in Q1 2019.
  • venBio Partners opened 1 new position and closed 0 in Q1 2019.
  • venBio Partners's portfolio value rose 224% quarter-over-quarter to $123M.

Based on venBio Partners's 13F filing for Q1 2019, filed 15 May 2019.